Unit of Orthopaedic Pathology and Osteoarticular Tissue Regeneration, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano 1/10, 40136, Bologna, Italy.
Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX, 77030, USA.
J Exp Clin Cancer Res. 2020 Feb 22;39(1):40. doi: 10.1186/s13046-020-01548-4.
Osteosarcoma (OS) is an aggressive malignant neoplasm that still suffers from poor prognosis in the case of distal metastases or occurrence of multi-drug resistance. It is therefore crucial to find novel therapeutic options able to go beyond these limitations and improve patients' survival. The objective of this study is to exploit the intrinsic properties of mesenchymal stromal cells (MSCs) to migrate and infiltrate the tumor stroma to specifically deliver therapeutic agents directly to cancer cells. In particular, we aimed to test the efficacy of the photoactivation of MSCs loaded with nanoparticles in vitro and in a murine in vivo ectopic osteosarcoma model.
AlPcS@FNPs were produced by adding tetra-sulfonated aluminum phthalocyanine (AlPcS) to an aqueous solution of positively charged poly-methyl methacrylate core-shell fluorescent nanoparticles (FNPs). The photodynamic therapy (PDT) effect is achieved by activation of the photosensitizer AlPcS in the near-infrared light with an LED source. Human MSCs were isolated from the bone marrow of five donors to account for inter-patients variability and used in this study after being evaluated for their clonogenicity, multipotency and immunophenotypic profile. MSC lines were then tested for the ability to internalize and retain the nanoparticles, along with their migratory properties in vitro. Photoactivation effect was evaluated both in a monolayer (2D) co-culture of AlPcS@FNPs loaded MSCs with human OS cells (SaOS-2) and in tridimensional (3D) multicellular spheroids (AlPcS@FNPs loaded MSCs with human OS cells, MG-63). Cell death was assessed by AnnexinV/PI and Live&Dead CalceinAM/EthD staining in 2D, while in the 3D co-culture, the cell killing effect was measured through ATP content, CalceinAM/EthD staining and TEM imaging. We also evaluated the effectiveness of AlPcS@FNPs loaded MSCs as delivery systems and the ability of the photodynamic treatment to kill cancer cells in a subcutaneous mouse model of OS by bioluminescence imaging (BLI) and histology.
MSCs internalized AlPcS@FNPs without losing or altering their motility and viability in vitro. Photoactivation of AlPcS@FNPs loaded MSCs induced high level of OS cells death in the 2D co-culture. Similarly, in the 3D co-culture (MSCs:OS ratios 1:1 or 1:3), a substantial decrease of both MSCs and OS cells viability was observed. Notably, when increasing the MSCs:OS ratio to 1:7, photoactivation still caused more than 40% cells death. When tested in an in vivo ectopic OS model, AlPcS4@FNPs loaded MSCs were able to decrease OS growth by 68% after two cycles of photoactivation.
Our findings demonstrate that MSCs can deliver functional photosensitizer-decorated nanoparticles in vitro and in vivo and inhibit OS tumor growth. MSCs may be an effective platform for the targeted delivery of therapeutic nanodrugs in a clinical scenario, alone or in combination with other osteosarcoma treatment modalities.
骨肉瘤(OS)是一种侵袭性恶性肿瘤,即使在发生远端转移或出现多药耐药的情况下,其预后仍较差。因此,寻找新的治疗方法以克服这些局限性并提高患者生存率至关重要。本研究旨在利用间充质基质细胞(MSCs)的固有特性迁移并浸润肿瘤基质,从而将治疗剂特异性递送至癌细胞。具体而言,我们旨在测试负载纳米粒子的 MSC 的光激活在体外和小鼠体内异位骨肉瘤模型中的疗效。
AlPcS@FNPs 通过将四磺酸基酞菁铝(AlPcS)添加到带正电荷的聚甲基丙烯酸甲酯核壳荧光纳米粒子(FNPs)的水溶液中制备而成。光动力疗法(PDT)效果通过近红外光激发光敏剂 AlPcS 来实现,光源为 LED。从五名供体的骨髓中分离出人 MSCs,以评估个体间变异性,并在评估其集落形成能力、多能性和免疫表型特征后用于本研究。然后测试 MSC 线内化和保留纳米粒子的能力以及体外迁移特性。光激活效果在人骨肉瘤细胞(SaOS-2)与人 MSC 的单层(2D)共培养物和三维(3D)多细胞球体(负载 AlPcS@FNPs 的人 MSC 与人骨肉瘤细胞、MG-63)中进行评估。通过 AnnexinV/PI 和 Live&Dead CalceinAM/EthD 染色评估 2D 中的细胞死亡,而在 3D 共培养物中,通过 ATP 含量、CalceinAM/EthD 染色和 TEM 成像测量细胞杀伤效果。我们还评估了负载 AlPcS@FNPs 的 MSC 作为递送系统的有效性,以及光动力治疗在 OS 皮下小鼠模型中杀死癌细胞的能力,通过生物发光成像(BLI)和组织学进行评估。
MSCs 在体外内化 AlPcS@FNPs 而不会丢失或改变其运动性和活力。负载 AlPcS@FNPs 的 MSC 的光激活在 2D 共培养物中诱导了高水平的 OS 细胞死亡。同样,在 3D 共培养物中(MSC:OS 比为 1:1 或 1:3),观察到 MSC 和 OS 细胞活力明显下降。值得注意的是,当 MSC:OS 比增加到 1:7 时,光激活仍导致超过 40%的细胞死亡。当在体内异位 OS 模型中进行测试时,负载 AlPcS4@FNPs 的 MSC 在两次光激活循环后能够使 OS 生长减少 68%。
我们的研究结果表明,MSCs 能够在体外和体内递送功能性光敏剂修饰的纳米粒子,并抑制 OS 肿瘤的生长。MSCs 可能是一种有效的靶向递送治疗性纳米药物的平台,可单独使用或与其他骨肉瘤治疗方式联合使用。